Evidence map›Paper›PMID 25217177›Full record

ReviewEuropean archives of psychiatry and clinical neuroscience2014

Multistage drug effects of ketamine in the treatment of major depression.

Martin Walter, Shijia Li, Liliana Ramona Demenescu

Abstract readReview
PubMed Publisher
In one paragraph

Review in European archives of psychiatry and clinical neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Region- and time- specific effects of ketamine on cerebral blood flow: a randomized controlled trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Trial
  3. Trial
  4. Default mode network connectivity change corresponds to ketamine's delayed glutamatergic effects.European archives of psychiatry and clinical neuroscience · 2020
    Trial
  5. Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Altered functional connectivity density in major depressive disorder at rest.European archives of psychiatry and clinical neuroscience · 2016
    Article
  15. Article
  16. Article
  17. Ketamine-an update on its clinical uses and abuses.CNS neuroscience & therapeutics · 2014
    Review
  18. Selected issues of the DGPPN Congress in 2013.European archives of psychiatry and clinical neuroscience · 2014
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Martin WalterClinical Affective Neuroimaging Laboratory (CANLAB), Otto-von-Guericke-University, ZENIT, Leipziger Str. 44, 39120, Magdeburg, Germany, martin.walter@med.ovgu.de.
Shijia Li
Liliana Ramona Demenescu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A substantial number of patients diagnosed with major depression disorder show poor or no response to standard antidepressive drugs. Recent studies showed that ketamine promotes a rapid and sustained antidepressive effect in treatment-resistant depression. Importantly, after a single dose, such antidepressant action appears very fast, reaching maximum efficacy after 1-2 days before it slowly decays after 3-7 days. This temporal pattern is especially interesting since most effects are investigated following single, subanesthetic doses. This means that effects are observed at time points when the blood levels have long fallen below any active threshold. Mechanisms of action thus may be sought either in secondary or compensatory processes, which develop after acute systemic derangement or in molecular downstream mechanisms of action, which after initiation do not require the presence of active drug levels. We here review acute and delayed effects of subanesthetic ketamine infusion and discuss potential origins of antidepressant drug action. We will provide evidences that both acute effects on abnormal network configuration and delayed effects at the level of homeostatic synaptic plasticity may be necessary for antidepressant action. We further argue that such effects should be followed by a temporally well-defined exploitation of these transient changes by therapeutic processes, aiming at sustained changes of network configuration via psychotherapeutic or other methods.

Indexed as

AnalgesicsBrainHumansKetamineMajor Depressive DisorderTime FactorsTreatment OutcomeAnalgesicsKetamine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.